Pfizer Inc. (NYSE:PFE) Stock Holdings Lessened by Procyon Advisors LLC

Procyon Advisors LLC lowered its stake in Pfizer Inc. (NYSE:PFEGet Rating) by 10.6% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 24,789 shares of the biopharmaceutical company’s stock after selling 2,929 shares during the period. Procyon Advisors LLC’s holdings in Pfizer were worth $1,300,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of PFE. KRS Capital Management LLC purchased a new position in Pfizer during the 4th quarter worth approximately $216,000. American International Group Inc. grew its position in Pfizer by 1.0% during the 4th quarter. American International Group Inc. now owns 1,628,113 shares of the biopharmaceutical company’s stock worth $96,140,000 after purchasing an additional 16,271 shares in the last quarter. Schroder Investment Management Group grew its position in Pfizer by 17.5% during the 4th quarter. Schroder Investment Management Group now owns 10,536,659 shares of the biopharmaceutical company’s stock worth $622,190,000 after purchasing an additional 1,567,089 shares in the last quarter. Quilter Plc grew its position in Pfizer by 17.0% during the 4th quarter. Quilter Plc now owns 1,155,490 shares of the biopharmaceutical company’s stock worth $65,459,000 after purchasing an additional 168,009 shares in the last quarter. Finally, Williams Jones Wealth Management LLC. grew its holdings in shares of Pfizer by 6.1% during the 4th quarter. Williams Jones Wealth Management LLC. now owns 166,472 shares of the biopharmaceutical company’s stock valued at $9,830,000 after acquiring an additional 9,607 shares in the last quarter. Institutional investors own 67.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on PFE. UBS Group set a $59.00 price target on shares of Pfizer in a report on Thursday, September 1st. Berenberg Bank set a $44.00 price target on shares of Pfizer in a report on Wednesday, September 14th. Barclays set a $50.00 price target on shares of Pfizer in a report on Thursday, September 1st. JPMorgan Chase & Co. set a $57.00 price target on shares of Pfizer in a report on Tuesday, June 28th. Finally, Morgan Stanley decreased their price objective on shares of Pfizer from $52.00 to $49.00 and set an “equal weight” rating for the company in a report on Friday, July 8th. Nine analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Pfizer has a consensus rating of “Moderate Buy” and an average target price of $57.00.

Pfizer Stock Performance

PFE opened at $46.03 on Monday. The firm has a market capitalization of $258.34 billion, a P/E ratio of 9.01, a price-to-earnings-growth ratio of 0.56 and a beta of 0.70. The stock’s 50 day moving average price is $48.99 and its two-hundred day moving average price is $50.45. The company has a quick ratio of 1.20, a current ratio of 1.42 and a debt-to-equity ratio of 0.39. Pfizer Inc. has a 12-month low of $40.94 and a 12-month high of $61.71.

Pfizer (NYSE:PFEGet Rating) last released its earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.95 by $0.09. The firm had revenue of $27.74 billion for the quarter, compared to analyst estimates of $26.20 billion. Pfizer had a return on equity of 43.18% and a net margin of 28.92%. The company’s revenue was up 46.8% on a year-over-year basis. During the same quarter last year, the firm posted $1.07 EPS. On average, equities analysts forecast that Pfizer Inc. will post 6.54 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 6th. Shareholders of record on Wednesday, June 29th were issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 3.48%. The ex-dividend date of this dividend was Thursday, July 28th. Pfizer’s dividend payout ratio (DPR) is currently 31.31%.

Pfizer Company Profile

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Read More

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.